NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
Similar Posts
Glaxo Pricing Under DOJ investigation / GAO Report Says Medicaid Overpays for Drugs
Glaxo Pricing Under DOJ investigation / GAO Report Says Medicaid Overpays for Drugs Wed, 9 Mar 2005 Reuters reports that GlaxoSmithKline is under investigation by the Department of Justice concerning Medicaid drug pricing. The skyrocketing cost of drugs is depleting Medicaid, the nation’s largest health insturance program paid for by…
AHRP: Published NIMH Funded Prozac Trial Report Concealed Suicide Attempts by Teens
Recent revelations indicate that pharmaceutical companies have selectively reported partial (favorable) clinical trial results from pediatric antidepressant trials and concealed evidence of harm from physicians, other health care professionals, and the public. It is universally agreed in the literature that failure to disclose all trial results compromises physicians’ ability to provide professional care – thereby increasing the likelihood of causing preventable harm. More generally, failure to disclose trial results in scientific publications taints the scientific literature (by rendering it not credible) and, as New York State Attorney General Elliot Spitzer charged recently, constitutes plain and simple fraud.
British Rethinking Rules After Ill-Fated Drug Trial_NYT
A front page report in The New York Times provides additonal information about the catastrophic TGN1412 medical experiment in which 6 previously healthy volunteers were intravenously injected with monoclonal antibody in a highly risky procedure.
Parity Likely to Increase Wholesale Sedation of Children
"For her last month of life, Kifuji overall prescribed 835 pills to Rebecca….If what Dr. Kifuji did in this case is the acceptable standard of care for children in Massachusetts, then there is something very wrong in this state."
Journals Must Exercise Their Authority as Gatekeepers
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.